(Q46810258)

25 December 2017

title

Elevated serum creatinine levels associated with fenofibrate therapy (English)

1 reference

25 December 2017

4

Amy Barton Pai

1 reference

25 December 2017

author name string

Charles R McQuade

series ordinal

1

1 reference

25 December 2017

Jennifer Griego

series ordinal

2

1 reference

25 December 2017

Joe Anderson

series ordinal

3

1 reference

25 December 2017

publication date

1 January 2008

1 reference

25 December 2017

American Journal of Health-System Pharmacy

published in

1 reference

25 December 2017

volume

65

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

138-141

1 reference

25 December 2017

Hypertriglyceridemia as a cardiovascular risk factor

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Fenofibrate-Induced elevation in serum creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Fibrates and renal function.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Effects of lipid-lowering agents in the Dahl salt-sensitive rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

A method for estimating the probability of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070005

31 March 2020

Identifiers

DOI

10.2146/AJHP070005

1 reference

25 December 2017

release_fvkunnxcg5ecjhbgxdpk4pncfa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fvkunnxcg5ecjhbgxdpk4pncfa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

25 December 2017